On May 16, 2025, Camp4 Therapeutics Corp announced new findings on their SYNGAP1-Related Disorders Program and updated their corporate presentation at a major gene therapy meeting. This press release includes positive data regarding increased protein levels in non-human primates and safety data from their Urea Cycle Disorders Program.